Failure of islet β-cell compensation for insulin resistance causes type 2 diabetes: What causes non-alcoholic fatty liver disease and non-alcoholic steatohepatitis?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 10, 2010, Pages 1594-1597

  Nolan, Christopher J ^a  

^a The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE ASSOCIATION; EDITORIAL; GENETIC ASSOCIATION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; GENE LOCUS; GENETIC POLYMORPHISM; GLUCOSE TOLERANCE; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESPONSE; INTRAABDOMINAL FAT; LIVER CELL CARCINOMA; METABOLIC SYNDROME X; OBESITY; OVERNUTRITION;

ADIPONECTIN; ALANINE AMINOTRANSFERASE; HEPATOCYTE NUCLEAR FACTOR 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POTASSIUM CHANNEL KCNQ1; SOMATOMEDIN BINDING PROTEIN 2; TRANSCRIPTION FACTOR 7 LIKE 2;

EID: 77957578731     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06473.x     Document Type: Editorial

References (23)

1. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J. Gastroenterol. Hepatol. 2010 25 : 672 690.
2. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J. Clin. Invest. 2006 116 : 1802 1812.
3. Shlomai A, Kariv R, Leshno M, Beth-Or A, Sheinberg B, Halpern Z. Large-scale population analysis reveals an extremely low threshold for "non-healthy" alanine aminotransferase that predicts diabetes mellitus. J Gastroenterol. Hepatol. 2010 25 : 1687 1691.
4. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr., Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005 54 : 3140 3147.
5. Hanley AJ, Williams K, Festa A et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004 53 : 2623 2632.
6. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J. Gastroenterol. Hepatol. 2007 22 : 1086 1091.
7. Yun JW, Cho YK, Park JH et al. Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int. 2009 29 : 525 529.
8. Sanyal D, Mukhopadhyay P, Pandit K, Mukhopadhyay S, Chowdhury S. Central obesity but not generalised obesity (body mass index) predicts high prevalence of fatty liver (NRFLD), in recently detected untreated, IGT and type 2 diabetes Indian subjects. J. Indian Med. Assoc. 2009 107 : 755 758.
9. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006 43 : S99 S112.
10. Moscatiello S, Manini R, Marchesini G. Diabetes and liver disease: an ominous association. Nutr. Metab. Cardiovasc. Dis. 2007 17 : 63 70.
11. Nolan CJ, Prentki M. The islet beta-cell: fuel responsive and vulnerable. Trends Endocrinol. Metab. 2008 19 : 285 291.
12. El-Assaad W, Buteau J, Peyot ML et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 2003 144 : 4154 4163.
13. Samaras K, Botelho NK, Chisholm DJ, Lord RV. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity (Silver Spring) 2010 18 : 884 889.
14. Kahn SE, Prigeon RL, McCulloch DK et al. Quantification of the relationship between insulin sensitivity and beta- cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993 42 : 1663 1672.
15. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur. J. Clin. Invest. 2002 32 (Suppl. 3 35 45.
16. Voight BF, Scott LJ, Steinthorsdottir V et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 2010 42 : 579 589.
17. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008 40 : 1461 1465.
18. He S, McPhaul C, Li JZ et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 2010 285 : 6706 6715.
19. Romeo S, Sentinelli F, Cambuli VM et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J. Hepatol. 2010 53 : 335 338.
20. Valenti L, Al-Serri A, Daly AK et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010 51 : 1209 1217.
21. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat. Genet. 2010 42 : 21 3.
22. Kantartzis K, Peter A, Machicao F et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009 58 : 2616 2623.
23. Musso G, Gambino R, Pacini G, Pagano G, Durazzo M, Cassader M. Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology 2009 49 : 426 435.